Secondary Hyperparathyroidism clinical trials

Explore recruiting secondary hyperparathyroidism clinical trials.

Recruiting secondary hyperparathyroidism studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Secondary Hyperparathyroidism trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Phase 3, Single-arm, Open-label, Multidose, Titration, Pharmacokinetic, Pharmacodynamic, and Safety Study of Etelcalcetide in Children and Adolescents ≥ 2 to < 18 Years of age with Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Maintenance Hemodialysis

Czechia, Greece, Germany, Italy, Belgium, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-1) WITH AN OPEN-LABEL EXTENSION

Poland, Portugal, Spain, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Dose-Titrated PLS240 in the Treatment of Secondary Hyperparathyroidism in Individuals with End Stage Kidney Disease on Hemodialysis (PATH-2) With an Open-Label Extension

Portugal, Bulgaria, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Secondary Hyperparathyroidism trials by city

Secondary Hyperparathyroidism in Toronto Secondary Hyperparathyroidism in Vancouver Secondary Hyperparathyroidism in Montreal Secondary Hyperparathyroidism in Calgary Secondary Hyperparathyroidism in Edmonton Secondary Hyperparathyroidism in Ottawa Secondary Hyperparathyroidism in Winnipeg Secondary Hyperparathyroidism in Quebec City Secondary Hyperparathyroidism in Hamilton Secondary Hyperparathyroidism in Kitchener Secondary Hyperparathyroidism in London Secondary Hyperparathyroidism in Halifax Secondary Hyperparathyroidism in New York Secondary Hyperparathyroidism in Los Angeles Secondary Hyperparathyroidism in Chicago Secondary Hyperparathyroidism in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease